Details

Autor(en) / Beteiligte

• Olofsson Bagge, Roger
• Holmberg, Carl Jacob
• Hieken, Tina J.
• Zager, Jonathan S.
• Long, Georgina V.
• Van Akkooi, Alexander Christopher Jonathan
• Karakousis, Giorgos C
• Pallan, Lalit
• Vetto, John T.
• Gyorki, David E.
• Ascierto, Paolo Antonio
• Dummer, Reinhard
• Hui, Jane Yuet Ching
• Schachter, Jacob
• Helgadottir, Hildur
• Kroon, Hidde
• Rothermel, Luke Daniel
• Carlino, Matteo S.
• Broman, Kristy Kummerow
• Ny, Lars

Titel

The efficacy of immune checkpoint blockade for melanoma in-transit with or without nodal metastases: A multicenter cohort study

Ist Teil von

• JOURNAL OF CLINICAL ONCOLOGY, 2022, Vol.40 (16_suppl), p.9569-9569

Erscheinungsjahr

2022

Link zum Volltext

Quelle

EZB Electronic Journals Library

Beschreibungen/Notizen

• 9569 Background: Guidelines addressing melanoma in-transit metastasis (ITM) recommend immune checkpoint inhibitors (ICI) as a first-line treatment option, despite the fact that there are no efficacy data available from prospective trials for exclusively ITM disease. The aim of this study was to analyze the outcome of patients with ITM treated with ICI based on data from a large cohort of patients treated at international high‐volume melanoma centers. Methods: A multicenter retrospective cohort study of patients treated between January 2015 and December 2020 from Australia, Europe, and USA, evaluating treatment with ICI for ITM with or without nodal involvement (AJCC8 N1c, N2c and N3c) and without distant disease (M0). Patients were treated with PD-1 inhibitor (nivolumab or pembrolizumab) and/or CTLA-4 inhibitor (ipilimumab). We assessed response rates, progression-free survival (PFS), melanoma-specific survival (MSS) and overall survival (OS). Results: A total of 287 patients from 21 institutions in 8 countries were included. Immunotherapy was first-line treatment in 64 (22%) patients. Monotherapy with a PD-1 or CTLA-4 inhibitor was given in 233 (81%) and 23 (8%) patients respectively, while 31 (11%) received both in combination. Overall response rate was 56%, complete response (CR) rate 36% and progressive disease (PD) rate 32%. Median PFS was 10 months (95% CI 7.4-12.6 months) with a 1-, 2- and 5-year PFS rate of 48%, 33% and 18% respectively. Median MSS was not reached, and the 1-, 2- and 5-year MSS rates were 95%, 83% and 71% respectively. Conclusions: Systemic immunotherapy is an effective treatment for melanoma ITM. Future studies should evaluate the optimal role for systemic immunotherapy in the context of multimodality therapy including locoregional treatments such as surgery, intralesional therapy, and regional therapies.